<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870623</url>
  </required_header>
  <id_info>
    <org_study_id>540-08-FB</org_study_id>
    <nct_id>NCT00870623</nct_id>
  </id_info>
  <brief_title>Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections</brief_title>
  <official_title>Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bloodstream infections (BSI) are a major cause of morbidity and mortality. Community-onset
      BSI have an overall attributable mortality of 10-13% while nosocomial BSI mortality ranges
      are quite variable from 12-80%. Bloodstream infections are also costly and result in
      prolonged hospital stays. Nosocomial BSIs have been shown to increase length of stay by 5-25
      days and increase costs $23,000 - 40,000 above matched controls. The duration of therapy
      necessary to clear blood stream infections is unknown and no study has systematically
      addressed this issue. The use of antimicrobials is also not without consequence. These
      include financial cost, side-effects, promotion of superinfection (especially Clostridium
      difficile-associated diarrhea), and the promotion of microbial resistance. We hypothesize
      that a procalcitonin (host biomarker) and endotoxin (microorganism biomarker)-guided
      treatment plan could significantly decrease unnecessary exposure to antibiotics in patients
      with bloodstream infections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the optimal length of treatment by observing the normalization of procalcitonin (PCT) and Endotoxin levels, compared with the length of treatment by standard of care.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if procalcitonin and endotoxin levels (or lack of decrease) are associated with treatment failure, complication, survival, cost, length of stay, progression to severe sepsis, or superinfections.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">223</enrollment>
  <condition>Bloodstream Infection</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (maximum 40mL) will be collected for future use or for purposes that are not integral
      to the current research.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized adult patients with positive blood cultures
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized, adult patient, at least one positive blood culture reported within 24
             hours of enrollment

        Exclusion Criteria:

          -  Previously enrolled in the study; discharged/deceased before first positive culture;
             receiving antibiotic for greater than or equal to 48 hours; endocarditis or
             osteomyelitis; antithymocyte globulin in the last 12 months; blood cultures positive
             for coagulase-negative staphylococcus only.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern GV. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol. 2003 Aug;41(8):3655-60.</citation>
    <PMID>12904371</PMID>
  </reference>
  <reference>
    <citation>Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004 Aug 1;39(3):309-17. Epub 2004 Jul 15. Erratum in: Clin Infect Dis. 2005 Apr 1;40(7):1077. Clin Infect Dis. 2004 Oct 1;39(7):1093.</citation>
    <PMID>15306996</PMID>
  </reference>
  <reference>
    <citation>Laupland KB, Gregson DB, Flemons WW, Hawkins D, Ross T, Church DL. Burden of community-onset bloodstream infection: a population-based assessment. Epidemiol Infect. 2007 Aug;135(6):1037-42. Epub 2006 Dec 7.</citation>
    <PMID>17156500</PMID>
  </reference>
  <reference>
    <citation>Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med. 2006 Oct;34(10):2588-95.</citation>
    <PMID>16915117</PMID>
  </reference>
  <reference>
    <citation>Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med. 1999 Sep;160(3):976-81.</citation>
    <PMID>10471627</PMID>
  </reference>
  <reference>
    <citation>Warren DK, Quadir WW, Hollenbeak CS, Elward AM, Cox MJ, Fraser VJ. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med. 2006 Aug;34(8):2084-9.</citation>
    <PMID>16763511</PMID>
  </reference>
  <reference>
    <citation>Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994 May 25;271(20):1598-601.</citation>
    <PMID>8182812</PMID>
  </reference>
  <reference>
    <citation>Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE; Infectious Diseases Society of America; American College of Critical Care Medicine; Society for Healthcare Epidemiology of America. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001 May 1;32(9):1249-72. Epub 2001 Apr 3. Review.</citation>
    <PMID>11303260</PMID>
  </reference>
  <reference>
    <citation>Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72.</citation>
    <PMID>17278083</PMID>
  </reference>
  <reference>
    <citation>Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999 Oct;29(4):745-58.</citation>
    <PMID>10589881</PMID>
  </reference>
  <reference>
    <citation>Corona A, Bertolini G, Ricotta AM, Wilson A, Singer M. Variability of treatment duration for bacteraemia in the critically ill: a multinational survey. J Antimicrob Chemother. 2003 Nov;52(5):849-52. Epub 2003 Sep 30. Erratum in: J Antimicrob Chemother. 2004 Jan;53(1):121. Wilson, A J Peter [corrected to Wilson, A Peter R].</citation>
    <PMID>14519681</PMID>
  </reference>
  <reference>
    <citation>Corona A, Wilson AP, Grassi M, Singer M. Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of short-course monotherapy. J Antimicrob Chemother. 2004 Oct;54(4):809-17. Epub 2004 Sep 16.</citation>
    <PMID>15375106</PMID>
  </reference>
  <reference>
    <citation>Rice LB. The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. Clin Infect Dis. 2008 Feb 15;46(4):491-6. doi: 10.1086/526535. Review.</citation>
    <PMID>18194098</PMID>
  </reference>
  <reference>
    <citation>Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004 Feb 21;363(9409):600-7.</citation>
    <PMID>14987884</PMID>
  </reference>
  <reference>
    <citation>Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93. Epub 2006 Apr 7.</citation>
    <PMID>16603606</PMID>
  </reference>
  <reference>
    <citation>Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007 Jan;131(1):9-19.</citation>
    <PMID>17218551</PMID>
  </reference>
  <reference>
    <citation>Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505. Epub 2007 Dec 20.</citation>
    <PMID>18096708</PMID>
  </reference>
  <reference>
    <citation>Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007 Mar;7(3):210-7. Review.</citation>
    <PMID>17317602</PMID>
  </reference>
  <reference>
    <citation>Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis. 2001 Jun 15;32(12):1718-25. Epub 2001 May 21.</citation>
    <PMID>11360214</PMID>
  </reference>
  <reference>
    <citation>Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006 Oct;34(10):2596-602.</citation>
    <PMID>16915118</PMID>
  </reference>
  <reference>
    <citation>Romaschin AD, Harris DM, Ribeiro MB, Paice J, Foster DM, Walker PM, Marshall JC. A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods. 1998 Mar 15;212(2):169-85.</citation>
    <PMID>9672205</PMID>
  </reference>
  <reference>
    <citation>Marshall JC, Walker PM, Foster DM, Harris D, Ribeiro M, Paice J, Romaschin AD, Derzko AN. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care. 2002 Aug;6(4):342-8. Epub 2002 May 2.</citation>
    <PMID>12225611</PMID>
  </reference>
  <reference>
    <citation>Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, Mehta S, Derzko A, Romaschin A; MEDIC study. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004 Aug 1;190(3):527-34. Epub 2004 Jul 2.</citation>
    <PMID>15243928</PMID>
  </reference>
  <reference>
    <citation>Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995 Jul 5;274(1):29-34.</citation>
    <PMID>7791255</PMID>
  </reference>
  <reference>
    <citation>McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis. 2007 Nov 1;45(9):1141-51. Epub 2007 Sep 26.</citation>
    <PMID>17918075</PMID>
  </reference>
  <reference>
    <citation>Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003 Nov 19;290(19):2588-98.</citation>
    <PMID>14625336</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Andre Kalil, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

